Please login to the form below

Not currently logged in
Email:
Password:

Xiaflex

This page shows the latest Xiaflex news and features for those working in and with pharma, biotech and healthcare.

Endo tries to ride out Valeant with $15.7bn bid for Salix

Endo tries to ride out Valeant with $15.7bn bid for Salix

a $2.6bn deal that added specialty medicine Xiaflex for fibrotic conditions affecting the fingers and penis.

Latest news

  • Endo to acquire Auxilium for $2.6bn Endo to acquire Auxilium for $2.6bn

    Auxilium's lead product is Xiaflex (collagenase clostridium histolyticum), which is approved in Europe for the treatment of Dupuytren's contracture, a condition that causes one or more fingers to bend ... We intend to leverage Auxilium's leading presence

  • Endo's $2.2bn bid for Auxilium Pharma could thwart QLT deal Endo's $2.2bn bid for Auxilium Pharma could thwart QLT deal

    Auxilium has 12 approved products in its portfolio, including a range of testosterone supplements headed by Testim Gel, as well as Xiaflex (collagenase clostridium histolyticum) for Dupuytren's contracture - a condition ... While Auxilium's entire

  • Auxilium's Xiaflex cleared in US for erection disorder Auxilium's Xiaflex cleared in US for erection disorder

    Auxilium's Xiaflex cleared in US for erection disorder. FDA approval to treat Peyronie's disease. ... The US Food and Drug Administration (FDA) cleared Auxilium Pharmaceutical's Xiaflex product to treat Peyronie's disease, a condition that causes painful

  • Pharma deals for February 2012 Pharma deals for February 2012

    76. Auxilium / Actelion (b). Commercialisation by Actelion. Xiaflex in registration for treatment of Dupuytren's contracture.

  • Extending the arsenal

    XIAFLEX (Auxilium Pharmaceuticals). Dupuytren's contracture. US. Capsaicin dermal patch. Qutenza (NeurogesX).

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics